RajaJRamachandranNMunnekeGPatelU. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol2006;61:142–53.
2.
OehrPBoucheloucheK. Imaging of prostate cancer. Curr Opin Oncol2007;19:259–64.
3.
KirkhamAPSEmbertonMAllenC. How good is MRI at detecting and characterising cancer within the prostate?Eur Urol2006; December (50):1163–75.
4.
HomJJCoakleyFVSimkoJPQayyumALuYProstate cancer: endorectal MR imaging and MR spectro-scopic imaging—distinction of true-positive results from chance-detected lesions. Radiology2006;238:192–9.
5.
CharlesworthPJHarrisAL. Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Pract Urol2006;3:157–69.
6.
WeidnerNCarrollPRFlaxJBlumenfeldWFolkmanJ. Tumour angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol1993;143:401–9.
7.
BorreMOffersenBVNerstromBOvergaardJ. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer1998;78:940–4.
8.
JagerGJRuijterETVan de KaaCAde la RosetteJJOosterhofGOThornburyJRDynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology1997;203:645–52.
9.
FüttererJJHeijminkSWScheenenTWVeltmanJHuismanHJVosPProstate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology2006;241:449–58.
10.
VillersAPuechPMoutonDLeroyXBallereauCLemaitreL. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol2006;176:2432–7.
11.
WeferAEHricakHVigneronDBCoakleyFVLuYWeferJSextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol2000;164:400–4.
HasumiMSuzukiKTaketomiAMatsuiHYamamotoTThe combination of multivoxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res2003;23:4223–7.
14.
SquillaciEManentiGMancinoSCarlaniMDi RomaMColangeloVMR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res2005;24:523–30.
15.
VilanovaJCBarceloJ. Prostate cancer detection: MR spectroscopic imaging. Abdom Imaging2007;32:253–61.
16.
YuKKScheidlerJHricakHVigneronDBZaloudekCJMalesRGProstate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology1999;213:481–8.
17.
WangLHricakHKattanMWChenHNScardinoPTKuroiwaK. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology2006;238:597–603.
18.
KurhanewiczJVigneronDBMalesRGSwansonMGYuKKHricakH. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am2000;38:115–38.
19.
ZakianKLSircarKHricakHChenHNShukla-DaveAEberhardtSCorrelation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology2005;234:804–14.
20.
desouzaNMReinsbergSAScurrEDBrewsterJMPayneGS. Magnetic resonance imaging in prostate cancer: value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol2007;80:90–5.
21.
DesouzaNMRichesSFVanasNJMorganVAAshleySAFisherCDiffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol2008;63:774–82.
22.
ChenAPCunninghamCHOzturk-IsikEXuDHurdREKelleyDAHigh-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging2007;25:1288–92.
23.
FeinsteinSB. The powerful microbubble: from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond. Am J Physiol Heart Circ Physiol2004:H450–7.
24.
ForsbergFMertonDALiuJBNeedlemanLGoldbergBB. Clinical applications of ultrasound contrast agents. Ultrasonics1998;36:695–701.
25.
MitterbergerMPinggeraGHorningerWBartschGStrasserHSchaeferGComparison of contrast-enhanced colour Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol2007;178:464–8.
26.
MitterbergerMPinggeraGHorningerWStrasserHHalpernEPallweinLDutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection. Eur Urol2008;53:112–7.
27.
OphirJCespedesIPonnekantiHYazdiYLiX. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrason Imag1991;13:111–34.
28.
PesaventoAPerreyCKruegerMErmertH. A time efficient and accurate strain estimation concept for ultrasonic elastography using interactive phase zero estimation. IEEE Trans Ultrason Ferroelectr Freq Control1999;46:1057–67.
29.
PallweinLMitterbergerMStruvePHorningerWAignerFBartschG. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol2007;17:2278–85.
30.
NelsonEDSlotoroffCBGomellaLGHalpernEJ. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology2007;70:1136–40.
31.
SalomonGKöllermanJThederanIChunFKBudäusLSchlommTEvaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol2008 [EPub ahead of print].
32.
PallweinLAignerFFaschingbauerRPallweinEPinggeraGBartschGProstate cancer diagnosis: value of real-time elastography. Abdom Imaging2008 [EPub ahead of print].
33.
PallweinLMitterbergerMPinggeraGAignerFPedrossFGradlJ. Sonoelastography of the prostate: comparison with systematic biopsy findings in 492 patients. Eur J Radiol2008;65:304–10.
34.
BraeckmanJAutierPGarbarCMarichalMPSovianyCNirRComputer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int2008;101:293–8.
35.
BraeckmanJAutierPSovianyCNirRNirDMichielsenDThe accuracy of transrectal ultrasound supplemented with Prostate HistoScanning™ for detection of small prostate cancers. BJU Int.2008 [Epub ahead of print].
36.
WiseAMStameyTAMcNealJEClaytonJL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology2002;60:264–9.
37.
HarndenPShelleyMDNaylorBColesBMasonMD. Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review. Eur Urol2008 [Epub ahead of print].
38.
National Institute of Clinical Excellence (UK). NICE prostate cancer management guidelines. www.nice.org.uk.
39.
TrueLD. Surgical pathology examination of the prostate gland: practice survey by the American Society of Clinical Pathologists. Am J Clin Pathol1994;102:572–9.
40.
BossuytPMIrwigLCraigJGlasziouP. Comparative accuracy: assessing new tests against existing diagnostic pathways. BMJ2006;332:1089–92.
41.
KumarRNayyarRKumarVGuptaNPHemalAKJagannathanNRPotential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10ng/mL: a follow-up study. Urology2008 [Epub ahead of print].
42.
PrestiJCJrProstate biopsy: how many cores are enough?Urol Oncol2003;21:135–40.
43.
MerrickGSGutmanSAndreiniHTaubenslagWLindertDLCurtisRProstate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol2007;52:715–23.
44.
Van AsNJParkerCC. Active surveillance with selective radical treatment for localized prostate cancer. Cancer J2007;13:289–94.
45.
EggenerEScardinoPTCarrollPRZelefskyMJSartorOHricakHFocal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol2007;178:2260–7.
46.
AhmedHUPendseDIllingRAllenCvan der MeulenJHEmbertonM. Will focal therapy become a standard of care for men with localized prostate cancer?Nat Clin Pract Oncol2007 November;4:632–42.
